gi-6207

mCRC

ImmunityBio, Inc.vaccinePhase 1/2Dormant

C

33/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 18/ 100
Competitive Position: 81/ 100

Competitive context

12 Active assets in the mCRC cohort.

Asset / Sponsor	Phase	Rating
Calcium folinate pentahydrate Shanghai Henlius Biotech	Phase 2	B
FLUOROURACILUM Shanghai Henlius Biotech	Phase 2	B
Eloxatin Shanghai Henlius Biotech	Phase 2	B
Tuvonralimab Huazhong University of Science and Technology	Phase 2	CCC
Pelareorep Oncolytics Biotech	Phase 2	CCC

View all 20 →

Same molecule, other indications

gi-6207 is also rated in:

triple-negative breast carcinomaDormant

CC

Indicative ·

41 / 100

malignant pancreatic neoplasmDormant

C

Indicative ·

36 / 100

colorectal cancerDormant

C

Indicative ·

34 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.